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Abstract
Background: Leukotriene B4 (LTB4R and LTB4R2) and cysteinyl leukotriene receptors (CYSLTR1 and CYSLTR2)
contribute to malignant cell transformation. We aimed to investigate the expression of LTB4R, LTB4R2, CYSLTR1 and
CYSLTR2 in esophageal squamous cell carcinoma and adjacent non-transformed squamous epithelium of the
esophagus, as well as in control biopsy samples from esophageal squamous epithelium of patients with functional
dyspepsia.
Methods: Expression of LTB4R, LTB4R2, CYSLTR1 and CYSLTR2 was analyzed by immunohistochemistry (IHC) and
quantitative reverse transcription-polymerase chain reaction (qRT-PCR) in biopsy samples of 19 patients with
esophageal squamous cell cancer and 9 sex- and age-matched patients with functional dyspepsia.
Results: LTB4R, LTB4R2, CYSLTR1 and CYSLTR2 were expressed in all biopsy samples. Major findings were: 1) protein
levels of all leukotriene receptors were significantly increased in esophageal squamous cell cancer compared to
control mucosa (p < 0.05); 2) CYSLTR1 and CYSLTR2 gene expression was decreased in cancer tissue compared to
control at 0.26–fold and 0.23–fold respectively; 3) an up-regulation of LTB4R (mRNA and protein expression) and a
down-regulation of CYSLTR2 (mRNA expression) in non-transformed epithelium of cancer patients compared to
control (p < 0.05) was observed.
Conclusions: The expression of leukotriene receptors was deregulated in esophageal squamous cell cancer.
Up-regulation of LTB4R and down-regulation of CYSLTR2 gene expression may occur already in normal squamous
esophageal epithelium of patients with esophageal cancer suggesting a potential role of these receptors in early
steps of esophageal carcinogenesis. Larger studies are warranted to confirm these observations.
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Background
The incidence of squamous cell carcinoma of the
esophagus (ESCC) varies widely in the world, with age-
adjusted incidence rates ranging from 5 to 100/100.000
inhabitants/year [1]. In Europe, the incidence of this
subtype of esophageal cancer is of 5.4/100.000 for men
and 1.1/100.000 for women, with highest rates in
Scotland (13/100.000 for men and 4/100.000 for women)
and lowest rates in Greece and Bulgaria (below 2/
100.000 for men and 0.5/100.000 for women) [2]. In
Germany the incidence is of 6–10/100.000, occurring
four times more often in men than in women [3]. The
prognosis is poor, with only 1 on 5 patients surviving 3
years or more after the initial diagnosis [4]. Many epi-
demiological studies have demonstrated that hazardous
alcohol consumption and tobacco smoking increase the
risk of ESCC [5–7].
Leukotrienes belong to the large group of eicosanoids
that originate from the oxidative degradation of
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arachidonic acids [8]. Eicosanoids have pleiotropic ef-
fects on various cellular functions and numerous studies
have shown their role in the pathogenesis of chronic in-
flammation and cancer [9, 10]. In particular, recent stud-
ies have shown an involvement of leukotriene receptors
in the development of carcinomas of the pancreas, stom-
ach, colon, urinary bladder and ovary [11–15].
We hypothesized that the expression of these recep-
tors might be deregulated also in ESCC. Therefore, the
expression pattern of the two leukotriene B4 receptors
LTB4R and LTB4R2 and the two receptors for cysteinyl
leukotrienes (CYSLTR1 and CYSLTR2) was studied by
immunohistochemistry and quantitative reverse
transcription-polymerase chain reaction (qRT-PCR) in a
prospective study cohort of patients with esophageal squa-
mous cell cancer. Tissue specimen from cancer and adja-
cent non-transformed squamous epithelium were analyzed.
Gene expression may also be deregulated in adjacent non-
transformed squamous epithelium of patients with esopha-
geal squamous cell cancer [16]. Thus, a control group of
patients with functional dyspepsia was recruited.
Methods
Study population
The study was conducted according to the declaration of
Helsinki of 1975, as revised in 1983 and was approved
by the Ethics Committee of the Otto-von-Guericke Uni-
versity Hospital of Magdeburg (No. 34/08). All subjects
provided written informed consent before entering the
study. Nineteen newly diagnosed patients with ESCC
were prospectively enrolled from March 2009 to April
2010 at the Otto-von-Guericke University Hospital,
Magdeburg, Germany. After overnight fasting all indi-
viduals underwent upper gastrointestinal endoscopy with
videogastroscope (GIF Q145 or GIF Q180, Olympus
Medical, Hamburg, Germany). The following exclusion
criteria were applied: malignancies other than ESCC,
lack of signed informed consent, clinically instable pa-
tient. None of the patients with ESCC had chemother-
apy, radiotherapy or surgery prior to endoscopy. For
each patient four biopsies each were collected from the
tumor and from macroscopically non transformed mu-
cosa. Two biopsies were sent to the pathologist for hist-
ology, one biopsy was immediately snap-frozen in liquid
nitrogen and stored at -80 °C and one other was directly
paraffin embedded. Narrow-band imaging was used to
better demarcate neoplastic lesions from the surround-
ing normal non neoplastic mucosa. Lugol’s chromoendo-
scopy was used to further investigate flat lesions
suspicious of being cancerous.
Nine sex- and age-matched subjects (±4 years) under-
going upper GI endoscopy for dyspeptic symptoms were
enrolled as control group. Exclusion criteria were: the
presence of typical symptoms for gastro-esophageal
reflux disease, the intake of proton pump inhibitors in
the last 2 weeks, and/or the presence of esophageal ero-
sions at endoscopy. Control biopsies were collected at
least 2 cm cranial to the Z-line and subsequently snap
frozen or directly paraffin embedded as mentioned
above.
Structured questionnaire
Patients enrolled prospectively and controls were inter-
viewed within 2 days before undergoing upper GI
endoscopy using a structured questionnaire, providing in-
formation on demographics, medical history, smoking
habits, alcohol intake and proton pump inhibitor (PPI) in-
take. The english version of the study questionnaire is
shown in the Additional file 1. As there is no safe level of
smoking [17], patients were classified into current smokers
(within the past 12 months), former smokers and patients
who never smoked. Alcohol consumption was conse-
quently classified in 3 categories as most guidelines in dif-
ferent countries recommend that alcohol intake should not
exceed 20g/day for men and 10g/day for women [18]: ab-
stainers, low alcohol consumption (<20g/day for men,
<10g/day for women) and hazardous alcohol consumption
(≥20g/day for men, ≥10g/day women).
Extraction of total RNA, cDNA synthesis and quantitative
RT-PCR
Biopsies were stored at -80 °C and subjected to a two-step
RNA extraction protocol as described previously [19].
cDNA transcription was performed using 250 ng of total
RNA amount. In a final volume of 40 μl, 20 units of AMV
reverse transcriptase (Promega, Mannheim, Germany) in
the buffer containing 1x reaction buffer, 0.5 mM dNTP
(Roche, Mannheim, Germany), 10 mM random hexanu-
cleotides and 50 units of placenta RNase inhibitor (all re-
agents from Promega) were utilized. After incubation at
42 °C for 1 h enzymes were inactivated at 95 °C for 10
min and the reaction mixture was kept frozen at -80 °C
until enzymatic amplification. Quantitative RT-PCR was
performed using an iCycler (BioRad, Munich, Germany).
A typical 30 μl reaction mixture consisted of 15μl Hot-
StarTaq™ Master Mix, 1.2 μl of the RT-reaction, 0.3 μl
SYBR-Green I (1:10.000) (Molecular Probes, Eugene,
USA), and 0.25 μM of the specific primers for the gene
analyzed. Primary denaturation and activation of Taq-
polymerase at 95 °C for 15 min was followed by 40 cycles
with denaturation at 94 °C for 30 s, annealing at 60 °C for
30 s, and elongation at 72 °C for 30 s. The initial template
mRNA amounts were calculated by determining the time
point at which the linear increase of sample PCR product
started, relative to the corresponding points of a standard
curve; these are given as artificial units. All PCR products
were cloned into the pDIRECT™ (Qiagen, Hilden,
Germany) and used as internal standard for PCR. All PCR
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standard curves had correlation coefficients >0.95. β-actin
mRNA amounts were used to normalize the cDNA con-
tents of the different samples. The following primers were
used for the RT-PCR analysis: β-actin (fw: 5’-cat-gcc-atc-
ctg-cgt-ctg.gac-c-3’, rev: 5’-aca-tgg-tgg-tgc-cgc-cag-aca-g-
3’), LTB4R (fw: 5′-tca-gca-cca-tca-ggg-cag-tga-c-3′, rev:
5′-ctg-acc-ctg-gga-ttg-gca-tca-g-3′), LTB4R2 (fw: 5′-ggg-
tgt-aaa-ggg-acg-tgc-aca-g-3′, rev: 5′-gct-tgt-gct-gtt-tcc-




Immunohistochemical staining and cell count
Immunohistochemical analysis was performed using
the avidin-biotin complex immunostaining method
and the automated immunohistochemistry slide stain-
ing system by Ventana NexES (Ventana Medical Sys-
tem, Strasbourg, France). Tissue sections were
deparafinized, dehydrated and underwent antigen re-
trieval using a Dako protocol. Slides were incubated
with specific primary rabbit polyclonal antibodies for
LTB4R, LTB4R2, CYSLTR1 or CYSLTR2 (Cayman
chemicals, catalogue number 120114, dilution 1:100;
Acris, catalogue number SP4368P, dilution 1:25; GeneTex
Inc., catalogue number GTX70519, dilution 1:100; Life-
span Biosciences, catalogue number LS-A2255, dilution
1:100, respectively) either. All primary antibody incuba-
tions were followed by PBS-washing. Positive immunohis-
tochemical reactions were revealed using the iVIEWTM
DAB Detection Kit (Ventana, Germany). Specimens were
counterstained with hematoxylin and mounted with
DEPEX™. Specificity of immunostaining was checked with
non-immune serum. Samples were examined independ-
ently by CH and DJ. For LTB4R, LTB4R2, CYSLTR1 and
CYSLTR2, the staining intensity (SI) and the percentage of
positive cells (PP) were scored as followed: SI was classi-
fied in 0 (no staining), 1 (weak), 2 (moderate) and 3
(strong); PP: 0 (no positive cells), 1 (<10 %), 2 (10–50 %),
3 (51–80 %), 4 (>80 %). For each slide the immunoreactive
score (IRS) was calculated as SI x PP with a possible max-
imum score of 12. The esophageal mucosa consists of dif-
ferent layers including (from the basal membrane to the
lumen) basal stratum, spinosum stratum and superficial
stratum. An example for an absent staining is shown in
superficial cells of Fig. 1c (IRS = 0), whereas basal stratum
shows a weak SI (SI score = 1) for 10–50 % of cells in the
same picture (IRS = 2). A moderate staining is displayed in
figure 1G (SI score = 2) for >80 % of cancer cells (IRS = 8).
In 1H, superficial stratum shows a strong SI (SI score = 3)
for >80 % cells (PP score = 4) resulting in an IRS of 12. For
IRS assessment and statistical analysis we focused on the
sole basal stratum where (cancer) stem cells are supposed
to originate from [20].
Statistical analysis
All data were entered into a database and analyzed using
the R - 2.15.0. statistic software (free download on http://
www.r-project.org/). Wilcoxon signed-rank test and Mann-
Whitney U test were used for comparisons of the groups
where appropriate (2-sided). A statistical p-value <0.05 was
considered as significant for all comparisons. In order to re-
duce the chances of obtaining false-positive results due to
multiple comparisons (k = 12), Bonferroni correction
was applied to the p-value of comparisons concerning
immunohistochemistry of ESCC and basal stratum of
non-transformed epithelium in cancer patients and
control (p < 0.05).
Results
Overview on demographic population characteristics and
tumor location, staging and grading
Baseline data of ESCC patients are presented in Table 1.
The majority of subjects with ESCC and functional dys-
pepsia were male (14/19 and 5/9 respectively), and the
mean age was 62 ± 11 years in cancer patients and 61.6
± 12 years in controls. The most common symptoms re-
ported at admission from patients with ESCC were loss
of weight (60 %) and dysphagia (74.7 %), whereas only
28 % of patients reported heartburn and 25.3 %
odynophagia.
For each patient the alcohol consumption was also re-
corded. In 94.7 % of cases (18 of 19) alcohol consume
was accounted; 12/19 patients (63.2 %) were active alco-
hol consumer and 6/19 cases (31.6 %) were former
drinker. 1 patient (5.3 %) never drank alcohol. According
to the amount of alcohol, patients were considered low
alcohol consumer (5/19, 41.7%) and high alcohol con-
sumer (7/19, 58.3 %). Also smoking habits were recorded
and 11/19 cases (57.9 %) were considered active smoker,
whereas 8/19 patients (42.1 %) were former smoker in
the last year. There was no never smoker in cancer
patients.
Control group was composed by 9 sex-age matched
patients with dyspeptic symptoms: 5 men (55.5 %) and 4
female (44.5 %). For 6/9 controls, smoking habits and al-
cohol intake were recorded: 3/ 6 controls had never
smoked and further 3 controls were former smokers.
Four out of 6 controls reported to consume alcohol cur-
rently whereas 2 controls were abstainers. In 3 cases
questionnaires were not filled out before endoscopy. The
use of sedation for endoscopy hampered to obtain miss-
ing information afterwards. Patients were not contacted
again. No data on quantity of alcohol was available for
controls.
In Fig. 2 an overview on tumor characteristics is pre-
sented. Tumor location was documented as distance
from upper central incisor teeth. Distribution on upper
(15 – 23 cm), mid-thoracic (23 – 32 cm) and lower
Venerito et al. BMC Gastroenterology  (2016) 16:85 Page 3 of 9
esophagus (32 – 40 cm) was 3 (15,8 %), 8 (42,1 %) and 8
(42,1 %).
With respect to the tumor grading, 0, 11/19 (57.9 %),
7/19 (36.8 %) and 1 (5.3 %) patients had G1, G2, G3 and
G4, respectively.
According to the classification of the international Union
Contre le Cancer [21] stage I, II, III and IV were present in
2/19 (10.5 %), 2/19 (10.5 %), 4/19 (21.1%) and 11/19
(57.9 %) patients, respectively. None of the patients in the
control group had a malignancy of the upper GI tract.
Immunohistochemical expression of leukotriene receptors
in ESCC, non-transformed epithelium of cancer patients
and controls
Immunohistochemical staining was performed for all
cancers (19/19) and control patients (9/9), as well as 15/
19 normal esophageal epithelia of cancer patients. 4/19
biopsies from normal esophageal epithelia of cancer
patients contained insufficient tissue for immunohisto-
chemical evaluation. Raw data on immunohistochemical
expression of leukotriene receptors are provided in the
Fig. 1 Immunohistochemical localization of LTB4R/LTB4R2 and CYSLTR1/2. Leukotriene receptors are horizontally displayed from the top to the
bottom. Vertical sections represent the distinct histological tissues examined. Images show sections with low (large picture) and higher (right lower
corner) magnification example. In non-transformed mucosa of cancer patients and control mucosa, details display a representative section from basal
stratum with adjacent submucosal tissue. Furthermore, control panels show a mucosal papilla with circularly oriented basal membrane. Positive
receptor detection appears as brown staining (microscope: Nikon F200 camera 990). For LTB4R (a-c), the receptor is predominately located within the
cytosol of cancer cells and normal esophageal epithelium. Within the non-transformed epithelia LTB4R reaches medium (b) to low (c) staining intensity
in basal cells and a further reduction in luminal areas. The reactions for LTB4R2 also show a cytosolic receptor pattern (d-f). Non-cancerous tissues
(E and F) present low LTB4R2 expression in basal strata. An up-regulation of LTB4R2 can be seen in superficial epithelial layers instead. CYSLTR1 results
are demonstrated in the pictures below (g-i). Cancerous and non-cancerous epithelial esophageal cells present a cytosolic staining. As depicted,
CYSLTR1 is also located within the nuclei of cancer cells and non-transformed mucosa of patients with cancer (g and h). A weak CYSLTR1 expression is
present in basal stratum of the normal esophageal epithelium of cancer patients with up-regulation in superficial layers. CYSLTR1 staining remains low
across all cellular layers of dyspeptic control. CYSLTR2 is also localized within the cytoplasm (j-l). Both groups with normal esophageal epithelium
display a weak CYSLTR2 reactivity in basal compartments, whereas CYSLTR2 is up-regulated in luminal areas (i and l). ESCC = esophageal squamous cell
cancer; NTSE = non-transformed squamous epithelium of cancer patients; CSE = control squamous epithelium
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Additional file 2. For each receptor staining, compari-
sons were performed between cancer tissue and basal
strata of esophageal epithelium in cancer patients and
control. An overview on LTB4R, LTB4R2, CYSLTR1 and
CYSLTR2 receptors and their distinct expression profiles
in cancers and non-malignant tissue is presented in
Fig. 1. In cancerous and non-cancerous epithelial cells,
leukotriene receptors were located within the cytoplasm.
For CYSLTR1, nuclear receptor staining was also de-
tected in 14/19 ESCC (74 %) as well as in 12/15 non-
transformed mucosa specimen of patients with cancer
(80 %) and 6/9 in control (66 %). In the present study
we focused on the expression of leukotriene receptors in
cancer tissue and basal epithelial cells of the esophageal
mucosa. Statistical results regarding staining intensities
of the different leukotriene receptors are shown in
Table 2. IRS of LTB4R was medium in cancer tissue and
basal stratum of esophageal epithelium in cancer pa-
tients, whereas in control epithelium basal cells pre-
sented a weak reactivity. LTB4R protein expression was
increased in cancer and non-transformed epithelium of
cancer patients compared to control (p < 0.05), whereas
no difference in LTB4R expression was observed be-
tween ESCC and adjacent non-transformed epithelium
in cancer patients. IRS of LTB4R2, CYSLTR1 and
CYSLTR2 receptors were medium in cancer tissue but
low in normal epithelium of cancer patients and control
basal stratum. Protein expression of LTB4R2 and
CYSLTR2 was found to be significantly increased in can-
cer tissue compared to normal mucosa of cancer group
and control (p < 0.05). With respect to CYSLTR1 expres-
sion, cancer tissue displayed a significant up-regulation
compared to non-transformed squamous epithelium of
cancer patients (p < 0.05) but not to control epithelium
of dyspeptic patients. Protein expression of LTB4R2,
CYSLTR1 and CYSLTR2 in basal stratum of non-
transformed epithelium of cancer patients did not differ
from the corresponding layer in control.
Immune cells infiltrating cancerous and non-cancerous
tissue also presented a cytosolic and occasionally mem-
branous leukotriene receptor expression for the various
receptors.
Expression of LTB4R/LTB4R2 and CYSLTR1/CYSLTR2 mRNA
in cancer tissue, non-transformed epithelium of cancer
patients and control
Raw data on mRNA expression of leukotriene receptors
are provided in the Additional file 2. Figure 3 shows the
mRNA transcript level of LTB4R/LTB4R2 and CYSLTR1/
CYSLTR2 in the 3 groups. The LTB4R mRNA showed
an increase of the transcript in cancer tissue (1.69-fold)
and non-transformed esophageal epithelium of cancer
patients (2.24-fold) compared to control. The increase of
Fig. 2 Tumor characteristics. An overview of (a) tumor location, (b) tumor grading and (c) staging is given from the left to the right. In (a), the
tumor location is calculated as distance from upper central incisor teeth. Upper, mid-thoracic and lower third of the esophagus refer to 15 – 23
cm, 23 – 32 cm and 32 - 40 cm from upper incisor teeth, respectively. No G1 cancer was detected (b). Most cancers were in stage IV on initial
presentation (c). n = absolute number of patients; UICC = Union Contre le Cancer
Table 1 Baseline data of ESCC patients
N = 19 (%)
Male/female 14/5 (73.6/26.4)
Mean age (years) 62 ± 11
Alcohol consumption
Abstainer 1 (5.3)
Former drinking 6 (31.6)






Former smoker 8 (42.1)
Active smoker 11 (57.9)
Subjects were considered former drinkers of alcohol and former smokers
when no consumption was declared within the past 12 month, respectively.
The amount of male and female alcohol intake was differently classified into
(a) low (<20g/day for men, <10g/day for women) and (b) high risk (≥20g/day
for men, ≥10g/day women) intake. ESCC esophageal squamous cell cancer
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LTB4R mRNA in normal mucosa of patients with cancer
compared to control was statistically significant (p <
0.05). No significant differences were found between
ESCC and non-transformed mucosa in cancer patients.
The LTB4R2 transcript showed no statistically significant
difference between cancer tissue and the esophageal
squamous epithelium (patients with ESCC and control).
In cancer tissue, CYSLTR1 showed a decrease to 0.26-
fold in mRNA levels compared to control with statistical
significance (p < 0.05). Between cancers and non-
transformed mucosa of cancer patients, no differences
were statistically detectable. The expression of CYSLTR2
mRNA was reduced in cancer tissue to 0.23-fold and in
normal epithelium of cancer patients to 0.25-fold compared
to control. This reached statistical significance (p < 0.05).
Expression of leukotriene receptors and tumor stage
The clinical classification of tumor stages was performed
according to UICC [21]. As the numbers of patients in
stages I-III were small, stage I, II and III were grouped
together and compared with stage IV. There was no ob-
served difference in the expression of the receptors
LTB4R, LTB4R2, CYSLTR1 and CYSLTR2 between the
groups (Mann-Whitney U test).
Discussion
Herein we report for the first time the expression of leu-
kotriene receptors in ESCC as well as in esophageal
squamous epithelium of patients with and without
esophageal neoplasia. The role of leukotriene receptors
in immune cells is established [22], but their role in the
esophageal mucosa has not been investigated so far, and
thus future studies focusing on the physiological role of
leukotriene receptors in the esophageal mucosa are
warranted.
In the present study we report an up-regulation of
LTB4R protein in ESCC compared to control. Similarly, a
trend toward an up-regulation of LTB4R transcripts in
ESCC compared to control was observed. An up-
regulation of LTB4R protein has been reported in gastric
and pancreatic cancer as well [15, 23]. However,
combining the LTB4R antagonist LY293111 to gemcita-
bine did not add any benefit in terms of survival to
chemotherapy-naïve patients with advanced pancreatic
carcinoma [24]. Whether the use of a LTB4R antagonist
might be an option for treating ESCC has not been stud-
ied yet. LTB4R expression was observed to be increased in
the proliferative zone of gastric epithelium [25]. Moreover,
in a placebo controlled trial on human volunteers, the oral
LTB4-receptor antagonist VML295 diminished the prolif-
erative epidermal activity after traumatically induced skin
lesions [26]. LTB4R showed an up-regulation in prolifera-
tive areas of esophageal mucosa as well, suggesting a role
of this receptor for the proliferation of esophageal squa-
mous epithelium. Interestingly, an increased expression of
LTB4R was observed also in non-transformed esophageal
mucosa of cancer patients compared to control. This
phenomenon suggests a potential role of LTB4R in early
steps of esophageal carcinogenesis.
Table 2 Immunohistochemical expression of leukotriene
receptors
Immunoreactive score (IRS)
LTB4R LTB4R2 CYSLTR1 CYSLTR2
CSE median (range) 4 (0 - 8) 4 (4 - 6) 4 (4 - 8) 4 (-)
NTSE median (range) 8 (4 - 8) 4 (0 - 4) 4 (0 - 8) 4 (-)
ESCC median (range) 8 (4 - 12) 8 (4 - 12) 8 (4 - 12) 8 (4 - 12)
NTSE/CSE, p-value 0.034 0.588 1 1
ESCC/CSE, p-value 0.0016 0.016 0.252 0.016
ESCC/NTSE, p-value 1 0.0059 0.047 0.0234
IRS of all receptors are shown in the upper part of the table. Medians of IRS
and corresponding range of staining intensities are shown for each group. In
the lower part of the table comparisons between the different histological
groups are shown. For statistical analysis, Wilcoxon signed-rank test was
applied on groups of cancer patient whereas Mann-Whitney U test was used
for inter-individual comparisons. All p-values were multiplied by k = 12
(Bonferroni correction) and considered significant when <0.05. Significant
changes are displayed in bold letters. ESCC esophageal squamous cell cancer,
NTSE non-transformed squamous epithelium of cancer patients, CSE control
squamous epithelium; p < 0.05 (Wilcoxon signed-rank test, Mann-Whitney U
test, Bonferroni correction k = 12)
Fig. 3 mRNA expression of the leukotriene receptors in patients
with esophageal squamous cell cancer (cancer and non-transformed
mucosa) and in control. Logarithmic values were used to calculate
the representation of each box plot. Median values (line within the
box), and 25 % and 75 % quartiles (upper and lower box border) are
shown. Brackets represent significant 2-group comparisons. Dots
indicate values below or above the whiskers. a.u. = arbitrary units;
ESCC = esophageal squamous cell cancer; NTSE = non-transformed
squamous epithelium of cancer patients; CSE = control squamous
epithelium; * = p < 0.05 (Wilcoxon-Test, Mann-Whitney U-Test)
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LTB4R2 protein expression is also up-regulated in
ESCC whereas the specific transcripts did not show any
difference between cancerous and non-cancerous epithe-
lia. Previous studies have shown an increased LTB4R2
receptor expression in different epithelial cancers, sug-
gesting a role of this receptor in cancer spread [27, 28].
In a recent study on an orthotopic breast cancer model,
increasing the expression of the LTB4R2/LTB4/12(S)-
HETE receptor system by lipopolysaccharide stimulation
enhanced invasion of breast cancer cells, whereas its se-
lective inhibition turned out in a reduced number of
metastatic nodules [29]. Whether pharmacological inhib-
ition of LTB4R2 might offer new options for treatment
of ESCC has still to be determined.
LTB4R2 has not been described in normal esophageal
mucosa before. The expression of LTB4R2 has been re-
ported in different tissues and apart from its role in in-
flammatory cells LTB4R2 function needs to be clarified
[30]. In a mice model, LTB4R2 was found to be
expressed in colon cryptic cells and had a protective role
against dextran sodium sulfate (DSS)-induced colitis,
possibly by enhancing barrier function in epithelial cells
of the colon [31]. A protective function of the LTB4R2 is
to assume for the esophageal epithelium as well.
CYSLTR1 and CYSLTR2 proteins are up-regulated in
ESCC, while the specific transcripts show a down-
regulation compared to the esophageal mucosa of dyspep-
tic patients. An increased expression of CYSLTR1 recep-
tor protein was described in gastrointestinal and
urological malignancies before [15, 32], whereas a loss of
CYSLTR2 protein expression was shown in colon cancer
cells compared to non-malignant intestinal cells [33]. Ac-
cording to functional studies, CYSLTR1 mediates prefer-
entially pro-carcinogenic effects, whereas CYSLTR2 has
been associated with anti-tumor mechanisms. In a recent
study on colon cancer cells, CYSLTR1 signaling induced
β-catenin translocation and the activation of β-catenin tar-
get genes, resulting in increased proliferation and migra-
tion of colon cancer cells [34]. Furthermore, CYSLTR1
expression was correlated with enhanced levels of anti-
apoptotic proteins in colon cancer and CYSLTR1 transfec-
tion resulted in prolonged survival of Caco-2 cancer cells
in vitro [35]. With respect to the CYSLTR2 function, a
study on 329 colorectal cancers showed a more favorable
prognosis for patients with high nuclear CYSLTR2 stain-
ing in combination with low nuclear CYSLTR1 receptor.
Statistical analysis found high CYSLTR2 expression asso-
ciated with a decreased risk of death [36]. In another
study, aggressive CYSLTR2 negative breast cancer cells
(MDA-MB-231) exhibited a decrease in migratory cap-
acity after CYSLTR2 transfection which is associated with
a reduction in metastatic potential [37]. Whether
CYSLTR1 and CYSLTR2 might promote carcinogenesis
and spread of ESCC needs to be addressed in future
studies. The observed discordance between CYSLTR1,
CYSLTR2 protein expression and gene transcription can
be explained by the presence of leukotriene receptor
positive inflammatory cells infiltrating transformed
and non-transformed tissue of cancer patients. An in-
crease of β-actin in these leukocytes might have
biased RT-PCR results in these patients mocking a
total lower cysteinyl leukotriene receptor transcrip-
tion. Furthermore, within the esophageal mucosa, spi-
nosal and superficial cell layers constitute the main
part of cellular mass. In the immunohistochemical
analysis, the comparison was focused on the protein
expression of cancer tissue and basal stratum only
whereas in the RT-PCR all esophageal layers were an-
alyzed. Thus, methodological aspects explain the dif-
ferences between protein and mRNA expression
pattern of the different leukotriene receptors.
The expression of CYSLTR1 and CYSLTR2 receptors
was observed in non-transformed esophageal tissue as
well. Similarly, non-transformed esophageal mucosa of
cancer patients showed a significant reduction in
CYSLTR2 mRNA transcription compared to the esopha-
geal mucosa of dyspeptic control patients. Synthesis of
cysteinyl leukotriene by the esophageal mucosa has been
demonstrated, suggesting a physiological role of these
receptors within the esophageal mucosa [38]. Further
studies to define the role of cysteinyl leukotriene receptors
in esophageal squamous epithelium are warranted.
The relatively small groups of patients and controls
represent the major limitation of our study. This re-
sulted in limited statistical power for some of the sub-
groups analysis and prevented stratified analysis by sex
and some other risk modifiers. Moreover, the small
number of recruited patients may be responsible for the
lack of correlation between leukotriene receptor expres-
sion and ESCC stage (I-III versus IV). Larger studies
may provide clearer results.
Furthermore, all inflammatory cells revealed a con-
stant expression of leukotriene receptors. Cancerous and
non-cancerous tissue of patients often showed a varying
degree of inflammatory cell infiltration which may have
influenced results of RT-PCR.
In addition, biopsies were not checked by microdissec-
tion for content of cancerous and non-cancerous tissue.
Thus, the presence of non-transformed epithelium in
cancer samples cannot be excluded and may have influ-
enced results of mRNA analysis.
Another limitation is the observational character of this
study. Although we explored leukotriene receptor expres-
sion in ESCC, the functional relevance of this finding
remains to be determined. Functional research was not
planned beforehand. Future in vitro analysis using siRNA
knock-down techniques could clearly address this issue
elucidating the role of leukotriene receptors in ESCC.
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Conclusions
In the present study we report a deregulated expression
of leukotriene receptors in esophageal squamous cell
carcinoma. Furthermore, our results suggest a possible
up-regulation of LTB4R and down-regulation of
CYSLTR2 gene expression also in the adjacent non-
transformed squamous epithelium of the esophagus.
Our data may implicate a potential role of these recep-
tors in the early steps of esophageal carcinogenesis.
Further studies with a larger number of patients and
controls are warranted to validate our findings and to
determine clinical implications for therapeutic and pre-
vention purposes.
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